Cadrenal Therapeutics shareholders back share plan increase, warrant issuance at annual meeting

Cadrenal Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on September 24, 2026, according to an 8-K filed with the Securities and Exchange Commission. As of the July 27, 2026 record date, 3,567,592 shares of common stock were outstanding and entitled to vote, and 2,155,341 shares were present in person or by proxy, constituting a quorum.¹

Shareholders voted on five proposals. Quang X. Pham was elected as a Class I director, with 1,039,666 votes for and 14,342 withheld, to serve until the company's 2029 annual meeting and until a successor is duly elected and qualified.¹

Stockholders ratified the appointment of WithumSmith+Brown, P.C. to serve as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with 2,110,693 votes in favor, 39,121 against, and 5,527 abstentions.¹

On the plan amendment proposal, stockholders approved Amendment No. 2 to the company's 2022 Successor Equity Incentive Plan, increasing the shares available for awards by 323,542 to a total of 1,000,000 shares, with 694,746 votes for, 352,409 against, and 6,853 abstentions.¹

For the warrant proposal, stockholders approved, under Nasdaq Rule 5635(d), authorization to issue as many as 960,000 shares of common stock tied to the exercise of Series C-1 warrants issued as part of a private placement that closed on July 1, 2026, with 1,011,206 votes for, 34,449 against, and 8,353 abstentions.¹

Shareholders also approved a contingency measure allowing the meeting to be adjourned if more time were needed to secure votes for the plan or warrant proposals, though the company noted that because both proposals already had sufficient votes when the meeting convened, an adjournment was not necessary.¹